EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial)

Yoshiaki Nagatani, Naoko Chayahara, Hironaga Satake, Hisateru Yasui, Takeshi Sugimoto, Hirochika Toyama, Kazutoshi Tobimatsu, Eriko Ito, Yutaro Usui, Taiji Koyama, Shiro Kimbara, Yoshinori Imamura und 4 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.117034 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Yoshiaki Nagatani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Gemcitabine, Oxonic Acid, Paclitaxel. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: S-1 has demonstrated non-inferiority to gemcitabine (GEM) in overall survival (OS) in advanced pancreatic cancer and superiority in the adjuvant setting for resectable disease. This study evaluated the efficacy and safety of S-1 combined with GEM plus nab-paclitaxel (nPTX) in advanced pancreatic cancer. METHODS: This multicenter, single-arm, phase II study enrolled patients with previously untreated locally advanced, recurrent, or metastatic pancreatic cancer. Treatment consisted of GEM (600 mg/m²) and nPTX (90 mg/m²) on days 1 and 8 plus oral S-1 (50/70/80 mg/day according to body surface area) on days 1-14 of a 3-week cycle. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), OS, duration of response (DoR), primary tumor response, conversion rate, and safety. RESULTS: Between September 2018 and April 2024, 30 patients were enrolled. ORR was 63.3% (95% CI, 45.5-78.2), meeting the prespecified primary endpoint. PD was observed in only 6.7% of patients, resulting in a DCR of 86.7%. Median PFS and OS were 9.0 (95% CI, 7.5-10.5) and 15.0 months (12.6-17.4), respectively, and median DoR was 8.6 months (95% CI, 4.7-12.5). In locally advanced disease, ORR was 100.0%, and three of five patients (60.0%) underwent conversion surgery. Grade ≥ 3 adverse events were mainly hematologic, including neutropenia (43.3%), anorexia (6.7%), and biliary tract infection (6.7%), with no treatment-related deaths. CONCLUSION: The addition of S-1 to GEM plus nPTX demonstrated high antitumor activity, durable disease control, and encouraging conversion to resection, supporting further evaluation of this regimen, particularly in borderline resectable or locally advanced pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsGemcitabineOxonic AcidPaclitaxelPancreatic NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAlbuminsDrug CombinationsTegafur

Stichwörter der Autor:innen

GemcitabineNab-paclitaxelObjective response ratePancreatic cancerS-1

Substanzen

130-nm albumin-bound paclitaxelAlbuminsDrug CombinationsGemcitabineOxonic AcidPaclitaxelS 1 (combination)Tegafur

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
  • Department of Medical Oncology and Hematology, Konan Medical Center, Kobe, Japan.
  • Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan; Department of Medical Oncology, Kochi Medical School, Kochi University, Nankoku, Japan.
  • Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Hematology and Oncology, Kita-Harima Medical Center, Hyogo, Japan.
  • Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Zitieren

APA

Nagatani, Y., Chayahara, N., Satake, H., Yasui, H., Sugimoto, T., Toyama, H., Tobimatsu, K., Ito, E., Usui, Y., Koyama, T., Kimbara, S., Imamura, Y., Funakoshi, Y., Toyoda, M., Kiyota, N., & Minami, H. (2026). Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117034

Vancouver

Nagatani Y, Chayahara N, Satake H, Yasui H, Sugimoto T, Toyama H, et al. Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial). European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117034

BibTeX
@article{Nagatani2026,
  author = {Nagatani, Yoshiaki and Chayahara, Naoko and Satake, Hironaga and Yasui, Hisateru and Sugimoto, Takeshi and Toyama, Hirochika and Tobimatsu, Kazutoshi and Ito, Eriko and Usui, Yutaro and Koyama, Taiji and Kimbara, Shiro and Imamura, Yoshinori and Funakoshi, Yohei and Toyoda, Masanori and Kiyota, Naomi and Minami, Hironobu},
  title = {Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial)},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.117034}
}
Kostenlos starten →